Latest Breaking News On - Endocrine responsive breast cancer - Page 1 : comparemela.com

Dr Graff on the Impact of Endocrine Therapy Interruption on Conception in Breast Cancer Survivors

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

Stephaniel graffBrown university legorreta cancer centerBreast cancer translational research disease groupWarren alpert medical schoolLifespan cancer instituteBrown universityLegorreta cancer centerOnclive tvBreast cancerEndocrine therapy interruptionPhase 3 positive trialEndocrine responsive breast cancerHr positive breast cancer

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not experience worse short-term recurrence rates

Most were able to conceive and more than 60 per cent gave birth

United statesSan antonioAsia pacificAnn partridgeDana farber cancer instituteProfessor of medicine at harvard medical schoolSan antonio breast cancer symposiumNorth americanHarvard medicalPregnancy outcomeInterrupting therapyEndocrine responsive breast cancerNorth americaMiddle east

Breast cancer patients who discontinued endocrine therapy to continue pregnancy did not experience worse short-term recurrence rates

Breast cancer patients who discontinued endocrine therapy to continue pregnancy did not experience worse short-term recurrence rates
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesSan salvatoreSwitzerland generalSan antonioSouth koreaSchweizer frauenlaufCapelli cortiAsia pacificOlivia paganiGruppo giovani pazienti annaYong seop leeAnn partridgeBaillet latour fundBreast cancer research foundationGilson family foundationSwiss group for clinical cancer research

Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS® 2022

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that new data presentations.

San antonioUnited statesUnited kingdomJosepha sparanoGisela pedrozaRick baehnerFederico maiardiMegan jonesSciences corpSciences on facebookNational cancer instituteSciences on twitter exactsciencesCancer research groupExchange commissionGenomic health incSciences precision oncology portfolio

EXACT SCIENCES CORP: Exact Sciences Highlights the Impact of Precision Oncology Portfolio on Breast Cancer Treatment with 10 New Data Presentations at SABCS 2022

New independent clinical evidence from the pivotal TAILORx and RxPONDER trials support the role of the Oncotype DX Breast Recurrence Score test, the only genomic test to predict chemotherapy

San antonioUnited statesUnited kingdomJosepha sparanoGisela pedrozaRick baehnerFederico maiardiMegan jonesSciences corpSciences on facebookNational cancer instituteSciences on twitter exactsciencesCancer research groupExchange commissionPrnewswire exact sciences corpGenomic health inc